Blog
![Moleac awarded prize from Creative France – recognising the success of French entrepreneurs in Singapore](https://moleac.com/v3/wp-content/uploads/2022/03/creative-fr-996x675.jpeg)
Moleac awarded prize from Creative France – recognising the success of French entrepreneurs in Singapore
“Entrepreneur” is a French invention for risk takers committed to innovate, and Moleac is a complete illustration of successful entrepreneurial biopharmaceutical company in Singapore. A quote from his Excellency, Ambassador Benjamin Dubertret, French Ambassador in...
![Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study](https://moleac.com/v3/wp-content/uploads/2022/03/lab-research-2021-09-24-03-37-33-utc-min-1080x675.jpg)
Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study
Cerebrovasc Dis 2017; 43:36-42 Published by S. Karger AG, Basel This analysis from the CHIMES-E study shows that subjects with prognostic factors of poorer outcome get a higher benefit on post-stroke functional recovery with a 3-month course of NeuroAiD compared to...
![Moleac’s Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards](https://moleac.com/v3/wp-content/uploads/2022/03/WhatsApp-Image-2016-11-01-at-18.26.00-1-1080x675.jpeg)
Moleac’s Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards
NeuroAiD™ has been named New Product Innovation of the Year by Frost & Sullivan. This award recognizes healthcare products that are bringing innovative solutions for neurological disorders by pushing the boundaries of the usual practices. This award also...